$GNCA News
Last published 4y ago
- 4y agoGNCAGenocea Announces Wind Down of Operations and Delisting From NASDAQGlobeNewswireCAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company's ongoin
- 4y agoGNCAGenocea Initiates Restructuring and Announces Plan to Explore Strategic AlternativesGlobeNewswireCAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strat
- 4y agoATERGNCAIQNIO+1Thinking about buying stock in Nio, Genocea Biosciences, Phio Pharmaceuticals, IQIYI, or Aterian?PR NewswireNEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, GNCA, PHIO, IQ, and ATER. To
- 4y agoGNCAGenocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022GlobeNewswireGEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial tr
- 4y agoGNCAGenocea Biosciences to Host Investor WebinarGlobeNewswireCAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the
- 4y agoGNCAGenocea to Present at the 32nd Annual Oppenheimer Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, wil
- 4y agoGNCAGenocea Provides Fourth Quarter 2021 Corporate UpdateGlobeNewswireInitial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-genera
- 4y agoGNCAGenocea to Present Clinical and Preclinical Data at AACR Annual MeetingGlobeNewswireCompany to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably generates abundant, high-quality neoantigen-specifi
- 4y agoGNCAJohn Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that John Lunger, Chief Patient Supply Officer at Adaptimmu
- 4y agoGNCAGenocea to Host Fourth Quarter 2021 Corporate Update Conference Call & WebcastGlobeNewswireCAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update confer
- 4y agoGNCAGenocea to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will
- 4y agoGNCAGenocea to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferenc
- 4y agoGNCAGenocea Biosciences Provides Corporate UpdateGlobeNewswireEnters into Inhibigen™ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN™ trial CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company d
- 4y agoAALBBIOBIOLGNCA+1Thinking about buying stock in Biolase, BridgeBio Pharma, American Airlines, Expro Group, or Genocea Biosciences?PR NewswireNEW YORK, Dec. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOL, BBIO, AAL, XPRO, and GNCA. T
- 4y agoARDSAVCTGNCALICY+1Thinking about buying stock in Microbot Medical, Genocea Biosciences, Li-Cycle Holdings, American Virtual Cloud Technologies, or Aridis Pharmaceuticals?PR NewswireNEW YORK, Dec. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MBOT, GNCA, LICY, AVCT, and ARDS.
- 4y agoBFRIENSCGNCAIINN+1Thinking about buying stock in Ensysce Biosciences, Turkcell Iletisim Hizmetleri A.S., Genocea Biosciences, Inspira Technologies, or Biofrontera?PR NewswireNEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENSC, TKC, GNCA, IINN, and BFRI.
- 5y agoGNCAGenocea to Present at the Stifel 2021 Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will
- 5y agoGNCAGenocea Provides Third Quarter 2021 Corporate UpdateGlobeNewswireGEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Bioscienc
- 5y agoGNCAGenocea to Host Third Quarter 2021 Corporate Update Conference Call & WebcastGlobeNewswireCAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio
- 5y agoGNCAGenocea to Present at Upcoming ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferen
- 5y agoGNCAJennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commerc
- 5y agoGNCAGenocea to Present at Upcoming Scientific and Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual
- 5y agoGNCAGenocea Provides Second Quarter 2021 Corporate UpdateGlobeNewswireGEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWS
- 5y agoGNCAGenocea to Host Second Quarter 2021 Corporate Update Conference Call & WebcastGlobeNewswireCAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update confere
- 5y agoGNCAGenocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell TherapyGlobeNewswireCAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase
- 5y agoGNCAGenocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021GlobeNewswireFour of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months Two of seven CPI-refractory patients experienced stable dis
- 5y agoGNCAGenocea Biosciences, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / April 29, 2021 / Genocea Biosciences, Inc. (NASDAQ:GNCA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 29, 2021 at 8:30 AM Eastern Time. To listen to the event live or
- 5y agoGNCAGenocea To Host First Quarter 2021 Corporate Update Conference Call & WebcastGlobeNewswireCAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update con
- 5y agoGNCAGenocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021GlobeNewswirePro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance ...
- 5y agoGNCAGenocea to Present at the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
- 5y agoGNCAGenocea Provides Fourth Quarter 2020 Corporate UpdateGlobeNewswireGEN-011 and GEN-009 clinical trials continue to advance ATLASTM stimulatory antigen and inhibitory antigen (InhibigenTM) identification profiled in Cancer Discovery Announcing SARS-CoV-2 T cell...
- 5y agoGNCAGenocea to Host Fourth Quarter 2020 Corporate Update Conference Call & WebcastGlobeNewswireCAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth...
- 5y agoGNCAGenocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ PlatformGlobeNewswireStudy validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigensof anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T...
- 5y agoGNCAGenocea to Participate in the B. Riley Securities’ Virtual Oncology Investor ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
- 5y agoGNCAGenocea to Present at the H.C. Wainwright Virtual BioConnect ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
- 6y agoGNCAGenocea to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
- 6y agoGNCAGenocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020GlobeNewswireNovel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies GEN-011, a neoantigen-targeted peripheral...
- 6y agoGNCAGenocea to Host Investor Call Highlighting New GEN-009 Clinical and Immunogenicity Data to be Presented at Virtual SITC 2020GlobeNewswireCAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor...
- 6y agoGNCAGenocea Provides Third Quarter 2020 Corporate UpdateGlobeNewswireInitiated GEN-011 Phase1/2a clinical trial Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy ...
- 6y agoGNCAGenocea to Host Third Quarter 2020 Corporate Update Conference Call & WebcastGlobeNewswireCAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third...
- 6y agoGNCAGenocea Announces Upcoming Data Presentations at Virtual SITC 2020GlobeNewswireWill showcase clinical and immune responses from the ongoing GEN-009 Phase 1/2a trial Will provide a detailed introduction to GEN-011, an adoptive T cell therapy designed to improve upon the...
- 6y agoGNCAPFEMRKONCYNew Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%PR NewswireUSA News Group – A newly released report titled "Immunotherapy Drugs Market by Type, Therapy Area, End User - Global Forecast to 2025" forecasts the...
- 6y agoGNCAGenocea Announces FDA Acceptance of GEN-011 IND ApplicationGlobeNewswireCAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
- 6y agoGNCAGenocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020GlobeNewswireStep-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy 100% of patients have immune responses to...
- 6y agoGNCAGenocea to Present at the ESMO Virtual Congress and Two Investor Conferences in SeptemberGlobeNewswireCAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
- 6y agoGNCAGenocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint InhibitorsGlobeNewswireWebcast/conference call scheduled today, July 30th at 8:00 a.m. EDT Three of five patients achieved separate RECIST responses after GEN-009 administration GEN-009 elicited antigen-specific CD4+ and...
- 6y agoGNCAGenocea Provides Second Quarter 2020 Corporate UpdateGlobeNewswireUpcoming GEN-009 data update planned for July 30th at 8 a.m. EDTFiled IND application for GEN-011 and is working with the FDA to provide additional informationPrivate Placement with Leading Life...
- 6y agoGNCAGenocea Announces Private Placement Financing of Up to $80 MillionGlobeNewswireCAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has...
- 6y agoGNCAGenocea Biosciences Provides Clinical UpdateGlobeNewswireCAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced...
- 6y agoGNCAGenocea to Host Second Quarter 2020 Corporate Update Conference Call & WebcastGlobeNewswireCAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second...